## Drug Summary
S-EDDP, also known as the S-enantiomer of ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine, is a metabolite of methadone, an opioid used primarily for opioid maintenance therapy in opioid dependence and chronic pain management. S-EDDP itself does not have any specific therapeutic uses but its detection and quantification are relevant in the pharmacokinetic analysis of methadone metabolism. Methadone acts by binding to the mu-opioid receptor, mimicking the effects of endogenous opiates. It is known for its N-demethylation to form EDDP by cytochrome P450 enzymes, specifically CYP3A4 and CYP2B6.

## Drug Targets, Enzymes, Transporters, and Carriers
While S-EDDP itself is not known to have any specific targets, enzymes, transporters, or carriers, its parent drug methadone is metabolized mainly through CYP3A4 and CYP2B6. These enzymes are responsible for the conversion of methadone into EDDP and are crucial for its metabolism and subsequent excretion. Transporters involved in the methadone's pharmacokinetics include P-glycoprotein, which mediates its cellular transport influencing absorption and distribution within the body.

## Pharmacogenetics
Pharmacogenetic studies have primarily focused on the impact of genetic variations in CYP3A4 and CYP2B6 on the metabolism of methadone, although specific studies on S-EDDP are limited due to its role as a metabolite and not a therapeutic agent itself. Variants in these genes can significantly alter the metabolic rate of methadone, influencing both its efficacy and toxicity. For example, individuals with variant alleles in CYP2B6 that reduce the enzyme's activity might experience higher plasma levels of methadone, leading to increased effects or adverse reactions. Understanding these genetic variations is crucial for tailoring opioid therapy to ensure maximum efficacy while minimizing risks.